Literature DB >> 33549648

A retrospective review of autoimmune bullous disease antibody positivity before clinical symptoms.

Eli Raneses1, Meagan McGinley Simpson2, Alexandra Rosenberg1, Marcedes Coffman3, Jon Meyerle4.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33549648     DOI： 10.1016/j.jaad.2021.02.003

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  3 in total

1.  Bullous pemphigoid anti-BP180-NC16A autoantibody reactivity in healthy individuals is associated with marked hypovitaminosis D and Th2-like cytokine predominance.

Authors:  Stefan Tukaj; Katja Bieber; Wiebke Prüßmann; Jasper N Prüßmann; Enno Schmidt; Detlef Zillikens; Ralf J Ludwig; Michael Kasperkiewicz
Journal:  Arch Dermatol Res       Date:  2022-08-12       Impact factor: 3.033

2.  Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients.

Authors:  Antti Nätynki; Päivi Leisti; Jussi Tuusa; Outi Varpuluoma; Laura Huilaja; Kentaro Izumi; Sanna-Kaisa Herukka; Olavi Ukkola; Juhani Junttila; Nina Kokkonen; Kaisa Tasanen
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

Review 3.  The significance of preclinical anti-BP180 autoantibodies.

Authors:  Yosuke Mai; Kentaro Izumi; Shoko Mai; Hideyuki Ujiie
Journal:  Front Immunol       Date:  2022-08-08       Impact factor: 8.786
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.